Genus Stock Rating Lowered by Panmure Gordon (GNS)
Genus (LON:GNS) was downgraded by research analysts at Panmure Gordon to a “sell” rating in a report released on Friday, American Banking and Market News reports. They currently have a GBX 1,210 ($19.57) price target on the stock, down from their previous price target of GBX 1,500 ($24.26). Panmure Gordon’s price objective would indicate a potential downside of 10.10% from the stock’s previous close.
Genus (LON:GNS) traded up 0.82% during mid-day trading on Friday, hitting GBX 1346.00. The stock had a trading volume of 45,068 shares. Genus has a 52 week low of GBX 1270.5599 and a 52 week high of GBX 1609.00. The stock has a 50-day moving average of GBX 1377. and a 200-day moving average of GBX 1395.. The company’s market cap is £813.6 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Genus in a research note to investors on Tuesday, October 15th. They now have a GBX 1,850 ($29.92) price target on the stock. Separately, analysts at Nplus1 Brewin raised their price target on shares of Genus from GBX 1,348 ($21.80) to GBX 1,357 ($21.94) in a research note to investors on Tuesday, October 1st. They now have a “hold” rating on the stock. Finally, analysts at Liberum Capital reiterated a “buy” rating on shares of Genus in a research note to investors on Monday, September 23rd. They now have a GBX 1,550 ($25.06) price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of GBX 1,429.14 ($23.11).
Genus plc is a United Kingdom-based company. The Company is engaged in applying quantitative genetics and biotechnology to animal breeding in the bovine and porcine sectors.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.